AXSMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Axsome Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$155.81−1.33 (-0.85%)
Close on Oct 19, 2026
- Market cap
- $8.07B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$27.87 (+21.78%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Axsome Therapeutics, Inc. grew revenue 56.9% to $776.57M over the twelve months to Jun 30, 2026. Free cash flow was -$71.96M.
Revenue
$776.57M
+56.9% vs. a year earlier
Operating income
-$186.07M
TTM Q2 2026
Free cash flow
-$71.96M
TTM Q2 2026
EPS, diluted
-$3.75
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $8.07B
- P/E ratio
- –
- Price to sales
- 10.39
- Price to book
- 96.89
- Dividend yield
- –
- Free cash flow yield
- -0.89%
Fundamentals
- Revenue
- $776.57M
- Net income
- -$191.64M
- EPS, diluted
- -$3.75
- Free cash flow
- -$71.96M
- Book value per share
- $1.61
- Diluted shares
- 52M
Thirteen years at a glance
Fiscal years 2013 to 2025 and trailing twelve months, USD
Revenue
$776.57M+56.9% YoY
Gross profit
$724.04M+59.9% YoY
Operating income
-$186.07M
Net income
-$191.64M
EPS, diluted
-$3.75
Free cash flow
-$71.96M
Reported periodTrailing twelve months